137 related articles for article (PubMed ID: 7828277)
21. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
23. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.
Lai CL; Lau JY; Wu PC; Ngan H; Chung HT; Mitchell SJ; Corbett TJ; Chow AW; Lin HJ
Hepatology; 1993 Mar; 17(3):389-94. PubMed ID: 8383088
[TBL] [Abstract][Full Text] [Related]
24. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma.
Yuen MF; Ooi CG; Hui CK; Wong WM; Wong BC; Chan AO; Lai CL
Cancer; 2003 Jun; 97(11):2776-82. PubMed ID: 12767090
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
29. 4'-Epidoxorubicin (Epirubicin) as a single agent in advanced primary hepatocellular carcinoma--a preliminary experience.
Tan YO; Lim F
Ann Acad Med Singap; 1986 Apr; 15(2):169-71. PubMed ID: 3019215
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
[TBL] [Abstract][Full Text] [Related]
32. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
[TBL] [Abstract][Full Text] [Related]
33. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
[TBL] [Abstract][Full Text] [Related]
34. Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
Yuen MF; Hon C; Hui CK; Siu CW; Lai CL
J Clin Gastroenterol; 2002 Sep; 35(3):272-5. PubMed ID: 12192207
[TBL] [Abstract][Full Text] [Related]
35. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma.
Bhattacharya S; Novell JR; Dusheiko GM; Hilson AJ; Dick R; Hobbs KE
Cancer; 1995 Dec; 76(11):2202-10. PubMed ID: 8635022
[TBL] [Abstract][Full Text] [Related]
36. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
Miyaguchi S; Watanabe T; Takahashi H; Nakamura M; Saito H; Ishii H
Hepatogastroenterology; 2002; 49(45):724-9. PubMed ID: 12063979
[TBL] [Abstract][Full Text] [Related]
37. A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma.
Vorobiof DA; Bezwoda WR
Eur J Cancer; 1994; 30A(6):797-800. PubMed ID: 7917540
[TBL] [Abstract][Full Text] [Related]
38. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
39. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
Urabe T; Kaneko S; Matsushita E; Unoura M; Kobayashi K
Oncology; 1998; 55(1):39-47. PubMed ID: 9428374
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
